Catalent Inc.

100.97+4.28+4.43%Vol 669.33K1Y Perf -7.20%
May 26th, 2022 16:04 DELAYED
BID90.67 ASK113.01
Open96.79 Previous Close100.97
Pre-Market- After-Market100.97
 - -  - -%
Target Price
140.60 
Analyst Rating
Strong Buy 1.32
Potential %
39.25 
Finscreener Ranking
★★★★     53.48
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★     50.87
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★★+     62.32
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
25.99 
Earnings Rating
Neutral
Market Cap18.10B 
Earnings Date
3rd May 2022
Alpha0.01 Standard Deviation0.11
Beta1.44 

Today's Price Range

96.55101.62

52W Range

86.34142.64

5 Year PE Ratio Range

24.50112.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
0.78%
1 Month
14.40%
3 Months
-1.35%
6 Months
-23.69%
1 Year
-7.20%
3 Years
118.41%
5 Years
180.55%
10 Years
-

TickerPriceChg.Chg.%
CTLT100.974.28004.43
AAPL143.783.26002.32
GOOG2 165.9249.13002.32
MSFT265.903.38001.29
XOM96.640.34000.35
WFC45.601.48003.35
JNJ179.46-0.1600-0.09
FB191.637.80004.24
GE77.012.48003.33
JPM129.442.20001.73
Financial StrengthValueIndustryS&P 500US Markets
2.10
2.90
0.47
0.91
6.00
Leverage Ratio 2.30
ProfitabilityValueIndustryS&P 500US Markets
33.80
15.70
23.20
11.30
10.85
RevenueValueIndustryS&P 500US Markets
4.70B
26.24
21.60
16.88
Earnings HistoryEstimateReportedSurprise %
Q03 20220.891.0012.36
Q02 20220.790.857.59
Q01 20220.580.638.62
Q04 20211.011.086.93
Q03 20210.730.786.85
Q02 20210.500.5816.00
Q01 20210.330.330.00
Q04 20200.810.854.94
Earnings Per EndEstimateRevision %Trend
6/2022 QR1.09-2.68Negative
6/2022 FY3.562.30Positive
9/2022 QR0.690.00-
6/2023 FY4.021.26Positive
Next Report Date-
Estimated EPS Next Report0.89
Estimates Count5
EPS Growth Next 5 Years %17.30
Volume Overview
Volume669.33K
Shares Outstanding179.21K
Shares Float140.79M
Trades Count15.24K
Dollar Volume67.03M
Avg. Volume1.15M
Avg. Weekly Volume880.46K
Avg. Monthly Volume1.32M
Avg. Quarterly Volume1.25M

Catalent Inc. (NYSE: CTLT) stock closed at 100.97 per share at the end of the most recent trading day (a 4.43% change compared to the prior day closing price) with a volume of 669.33K shares and market capitalization of 18.10B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 17300 people. Catalent Inc. CEO is John R. Chiminski.

The one-year performance of Catalent Inc. stock is -7.2%, while year-to-date (YTD) performance is -21.14%. CTLT stock has a five-year performance of 180.55%. Its 52-week range is between 86.34 and 142.64, which gives CTLT stock a 52-week price range ratio of 25.99%

Catalent Inc. currently has a PE ratio of 36.00, a price-to-book (PB) ratio of 3.88, a price-to-sale (PS) ratio of 3.75, a price to cashflow ratio of 35.00, a PEG ratio of 2.32, a ROA of 5.21%, a ROC of 7.45% and a ROE of 11.92%. The company’s profit margin is 10.85%, its EBITDA margin is 23.20%, and its revenue ttm is $4.70 Billion , which makes it $26.24 revenue per share.

Of the last four earnings reports from Catalent Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.89 for the next earnings report. Catalent Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Catalent Inc. is Strong Buy (1.32), with a target price of $140.6, which is +39.25% compared to the current price. The earnings rating for Catalent Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catalent Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catalent Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 11.83, ATR14 : 4.02, CCI20 : 61.91, Chaikin Money Flow : 0.08, MACD : 0.13, Money Flow Index : 45.86, ROC : 6.88, RSI : 55.13, STOCH (14,3) : 92.26, STOCH RSI : 1.00, UO : 51.54, Williams %R : -7.74), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catalent Inc. in the last 12-months were: Alessandro Maselli (Sold 4 736 shares of value $603 083 ), Aristippos Gennadios (Sold 2 727 shares of value $349 187 ), Gregory T. Lucier (Sold 5 068 shares of value $645 407 ), John R. Chiminski (Sold 0 shares of value $-2 986 972 ), John R. Chiminski (Sold 208 262 shares of value $27 069 357 ), Jonathan Arnold (Sold 0 shares of value $-338 421 ), Jonathan Arnold (Sold 12 905 shares of value $1 782 080 ), Karen A. Flynn (Sold 2 472 shares of value $288 334 ), Kay A Schmidt (Sold 3 563 shares of value $457 590 ), Michael J. Grippo (Sold 4 204 shares of value $544 204 ), Peter Zippelius (Sold 3 487 092 shares of value $437 899 992 ), Ricardo Pravda (Sold 0 shares of value $-241 694 ), Ricardo Pravda (Sold 8 856 shares of value $1 103 071 ), Ricci S Whitlow (Sold 184 shares of value $18 836 ), Ricky Hopson (Sold 4 156 shares of value $473 974 ), Scott Gunther (Sold 5 252 shares of value $667 692 ), Steven L. Fasman (Sold 0 shares of value $-889 050 ), Steven L. Fasman (Sold 46 874 shares of value $5 950 785 ), Thomas P. Castellano (Sold 4 955 shares of value $646 339 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (72.73 %)
8 (72.73 %)
8 (72.73 %)
Moderate Buy
2 (18.18 %)
2 (18.18 %)
2 (18.18 %)
Hold
1 (9.09 %)
1 (9.09 %)
1 (9.09 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.32
Strong Buy
1.32
Strong Buy
1.32

Catalent Inc.

Catalent Inc is a specialty and generic drug manufacturing company. The company focuses on advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. The vast majority of Catalent's sales are generated in the United States, followed by Europe and the rest of the world. Most of the company's sales are derived from branded drug products. The company considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. It operates in four operating segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.

CEO: John R. Chiminski

Telephone: +1 732 537-6200

Address: 14 Schoolhouse Road, Somerset 08873, NJ, US

Number of employees: 17 300

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

68%32%

Bearish Bullish

71%29%

Bearish Bullish

52%48%

TipRanks News for CTLT

Thu, 05 May 2022 01:47 GMT Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), PTC Therapeutics (PTCT) and Surgery Partners (SGRY)

- TipRanks. All rights reserved.

Tue, 12 Apr 2022 03:36 GMT Catalent (CTLT) Gets a Hold Rating from Deutsche Bank

- TipRanks. All rights reserved.

News

Stocktwits